1
|
Ryan KE, Wiggins J, Higgins N, El-Hayek C, Stoove M. Improved capture of trans and gender-diverse people diagnosed with HIV infection in Victoria following refinement to notification form. HIV Med 2020; 21:e23-e24. [PMID: 32892456 PMCID: PMC7754111 DOI: 10.1111/hiv.12915] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2020] [Revised: 05/22/2020] [Accepted: 06/15/2020] [Indexed: 11/28/2022]
Affiliation(s)
- K E Ryan
- Disease Elimination Program, Burnet Institute, Melbourne, Vic, Australia.,Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, Vic, Australia
| | - J Wiggins
- Peer Advocacy Network for the Sexual Health of Trans Masculinities (PASH.tm), Melbourne, Vic, Australia
| | - N Higgins
- Department of Health and Human Services, Government of Victoria, Melbourne, Vic, Australia
| | - C El-Hayek
- Disease Elimination Program, Burnet Institute, Melbourne, Vic, Australia
| | - M Stoove
- Disease Elimination Program, Burnet Institute, Melbourne, Vic, Australia.,Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Vic, Australia
| |
Collapse
|
2
|
Ryan KE, Lane DA, Flynn A, Shepperd J, Ireland HA, Curtis JR. Dose Finding Study of a Low Molecular Weight Heparin, Innohep, in Haemodialysis. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1646407] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryA pilot investigation was performed with Innohep, a low molecular weight (LMWH) preparation (peak maximum molecular mass 3,000-6,000), to determine possible dose regimens for patients undergoing regular maintenance haemodialysis for chronic renal failure. Results from this study suggested that suppression of macroscopic clot formation and fibrinopeptide A (FPA), a marker of fibrin formation, could be achieved following bolus injections rather than bolus injections and an infusion. On the basis of these preliminary findings, a randomised crossover study was performed in eight patients undergoing regular maintenance haemodialysis for 5-7 h to determine the effective antithrombotic dose of this LMWH. Single i.v. bolus doses of 1,250 AFXa u, 2,500 AFXa u and 5,000 AFXa u (n = 7-8) were compared to an UFH regime of 5,000 iu + 1,500 iu/h. Excessive clot formation in the dialyser bubble trap, necessitating additional UFH to enable completion of a prolonged (up to 7 h) dialysis, was observed in all patients on the 1,250 AFXa u dose (mean duration of dialysis prior to UFH, 3 h) but in a single patient only receiving the other LMWH doses. A dose-related response in the AFXa activity, measured by chromogenic substrate (CS) assay was seen in the three LMWH groups, with levels declining significantly (p <0.05) from 1-7 h. This contrasted with the constant levels maintained during dialysis with UFH. FPA levels were significantly elevated after 2 h following the 1,250 AFXa u bolus and after 4 h following the 2,500 AFXa u bolus. There was no significant difference in FPA levels between the 5,000 AFXa u bolus and UFH. β-thromboglobulin (pTG) levels rose significantly towards the end of dialysis in all LMWH groups and, at 5 h, were significantly increased following the 5,000 AFXa u and 2,500 AFXa u doses when compared to the UFH regime. AFXa levels correlated negatively with FPA levels (r = -0.62; p <0.01). In conclusion, for administration of Innohep, a bolus dose of 2,500 AFXa u would appear to be sufficient for dialyses of short duration (up to 4 h), whilst a 5,000 AFXa u bolus is as effective as UFH for a 6 h dialysis. AFXa activity measured by CS assay is related to inhibition of fibrin formation and can be used for monitoring purposes.
Collapse
Affiliation(s)
- K E Ryan
- The Departments of Haematology and Medicine, Charing Cross and Westminster Medical School, London, UK
| | - D A Lane
- The Departments of Haematology and Medicine, Charing Cross and Westminster Medical School, London, UK
| | - A Flynn
- The Departments of Haematology and Medicine, Charing Cross and Westminster Medical School, London, UK
| | - J Shepperd
- The Departments of Haematology and Medicine, Charing Cross and Westminster Medical School, London, UK
| | - H A Ireland
- The Departments of Haematology and Medicine, Charing Cross and Westminster Medical School, London, UK
| | - J R Curtis
- The Departments of Haematology and Medicine, Charing Cross and Westminster Medical School, London, UK
| |
Collapse
|
3
|
Ryan KE, Lane DA, Flynn A, Ireland H, Boisclair M, Shepperd J, Curtis JR. Antithrombotic Properties of Dermatan Sulphate (MF 701) in Haemodialysis for Chronic Renal Failure. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1646318] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryThe therapeutic potential of the glycosaminoglycan (GAG), dermatan sulphate (DS), as an antithrombotic agent in humans has yet to be established. We have performed dose ranging studies of DS to determine its effectiveness as an antithrombotic agent in patients (n = 6–8) undergoing haemodialysis for chronic renal failure. In an initial study, Study 1, i.v. bolus doses of 2–4 mg/kg and 5–6 mg/kg DS were given to patients dialysing with polyacrylonitrile hollow fibre (PAN HF) membranes. In a second crossover study, Study 2, performed using cuprophane hollow fibre (CHF) membranes, i. v. bolus doses of 3 mg/kg and 6 mg/kg DS were compared to a standard unfractionated heparin (UFH) regime that has been shown previously to inhibit fibrin formation. Further infusion studies, Study 3 and Study 4 evaluated the antithrombotic efficacy of an i. v. DS bolus of 3 mg/kg plus an i. v. infusion of DS 0.6 mg kg-1 h-1 and a DS bolus of 5 mg/ kg plus an infusion of 1 mg kg-1 h-1 over 5 h, respectively. These studies were compared to standard UFH regimes in a randomised crossover design. Plasma levels of fibrinopeptide A (FPA) and thrombin-antithrombin (TAT) were used as markers of fibrin formation and thrombin generation during dialysis using both membranes.The changes in DS concentration following administration of the different doses were similar in Studies 1 and 2. However, the effectiveness of DS as an anticoagulant appeared to depend markedly on the different dialyser types used in the two studies. In Study 1, 13/14 dialyses required additional UFH to complete a normal ~6 h session and DS was unable to prevent thrombin and fibrin formation, as determined by measurement of plasma FPA and TAT. However, some dose related effects were observed in the levels of these markers. Furthermore, DS levels correlated with those of FPA and TAT. In Study 2, increasing doses of DS (3 mg/kg and 6 mg/kg), allowed longer dialysis sessions (mean 4.57 h c.f. 5.25 h), approaching that obtained with UFH regime (5.86 h). FPA and TAT generation were incompletely suppressed by both doses of DS; FPA rose significantly compared to that observed with the UFH regime, while TAT did not. While no significant differences in the activation markers were observed between the two DS doses, DS levels, taken as a whole, showed significant negative correlations with those of FPA and TAT Little effect on the KCCT was seen.In Study 3, 3/6 patients required additional UFH (mean dialysis duration with DS 4.33 h c. f. 5.67 h with UFH). Mean DS levels were maintained between 35–40 µg/ml. Mean plasma FPA levels were maintained at constant levels throughout dialysis following DS administration but were higher than those observed following the UFH regime. In Study 4 mean DS levels were
Collapse
Affiliation(s)
- K E Ryan
- The Departments of Haematology and Medicine, Charing Cross and Westminster Hospital and Medical School, Hammersmith, London, UK
| | - D A Lane
- The Departments of Haematology and Medicine, Charing Cross and Westminster Hospital and Medical School, Hammersmith, London, UK
| | - A Flynn
- The Departments of Haematology and Medicine, Charing Cross and Westminster Hospital and Medical School, Hammersmith, London, UK
| | - H Ireland
- The Departments of Haematology and Medicine, Charing Cross and Westminster Hospital and Medical School, Hammersmith, London, UK
| | - M Boisclair
- The Departments of Haematology and Medicine, Charing Cross and Westminster Hospital and Medical School, Hammersmith, London, UK
| | - J Shepperd
- The Departments of Haematology and Medicine, Charing Cross and Westminster Hospital and Medical School, Hammersmith, London, UK
| | - J R Curtis
- The Departments of Haematology and Medicine, Charing Cross and Westminster Hospital and Medical School, Hammersmith, London, UK
| |
Collapse
|
4
|
Ryan KE, Walsh JP, Corbett DR, Winter A. A record of recent change in terrestrial sedimentation in a coral-reef environment, La Parguera, Puerto Rico: a response to coastal development? Mar Pollut Bull 2008; 56:1177-1183. [PMID: 18359047 DOI: 10.1016/j.marpolbul.2008.02.017] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/12/2008] [Revised: 02/07/2008] [Accepted: 02/10/2008] [Indexed: 05/26/2023]
Abstract
Increased sediment flux to the coastal ocean due to coastal development is considered a major threat to the viability of coral reefs. A change in the nature of sediment supply and storage has been identified in a variety of coastal settings, particularly in response to European colonization, but sedimentation around reefs has received less attention. This research examines the sedimentary record adjacent to a coastal village that has experienced considerable land-use change over the last few decades. Sediment cores were analyzed to characterize composition and sediment accumulation rates. Sedimentation rates decreased seaward across the shelf from 0.85 cm y(-1) in a nearshore bay to 0.19 cm y(-1) in a fore-reef setting. Data reflected a significant (up to 2x) increase over the last approximately 80 years in terrestrial sediment accumulating in the back-reef setting, suggesting greater terrestrial sediment flux to the area. Reef health has declined, and increased turbidity is believed to be an important impact, particularly when combined with additional stressors.
Collapse
Affiliation(s)
- K E Ryan
- Department of Geological Sciences, East Carolina University, Greenville, NC 27858, USA.
| | | | | | | |
Collapse
|
5
|
Ryan KE, Casey SM, Canty MJ, Crowe MA, Martin F, Evans ACO. Akt and Erk signal transduction pathways are early markers of differentiation in dominant and subordinate ovarian follicles in cattle. Reproduction 2007; 133:617-26. [PMID: 17379656 DOI: 10.1530/rep-06-0130] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Dominant follicles are those that continue to develop and have the potential to ovulate while subordinate follicles regress. Characteristics of dominant follicles include a larger diameter, higher intrafollicular estradiol, and lower IGF-binding protein (IGFBP)-4 concentrations compared with other cohort follicles. Follicle development is regulated by endocrine hormones that act via intracellular signaling pathways. Here, we show the differences in Akt, Erk, c-Jun N-terminal protein kinase, and p-38 signaling pathways between dominant and subordinate follicles at the dominance stage of the follicle wave. However, earlier in the follicle wave (dominant follicle selection), there were only differences in the levels of Akt and Erk signal transduction proteins among dominant and subordinate follicles. Using this profile of Akt and Erk protein expression in granulosa and theca cells of selected dominant follicles compared with subordinate follicles, we suggest a predictive model to identify future dominant and subordinate follicles from the pool of otherwise similar cohort follicles at the time of follicle wave emergence. We conclude that the Erk and Akt signal transduction pathways are important for dominant follicle selection and development and, furthermore, that the observed differences in these pathways mark the future dominant follicle from subordinate follicles before differences in follicular diameter, follicular fluid estradiol, and IGFBP-4 concentrations are apparent.
Collapse
Affiliation(s)
- K E Ryan
- School of Agriculture, Food Science and Veterinary Medicine, College of Life Science, Conway Institute for Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland
| | | | | | | | | | | |
Collapse
|
6
|
Ryan KE, McCance DR, Powell L, McMahon R, Trimble ER. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis 2006; 194:e123-30. [PMID: 17145061 DOI: 10.1016/j.atherosclerosis.2006.11.007] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2006] [Revised: 11/01/2006] [Accepted: 11/02/2006] [Indexed: 11/22/2022]
Abstract
Obesity is a low grade inflammatory state associated with premature cardiovascular morbidity and mortality. Along with traditional risk factors the measurement of endothelial function, insulin resistance, inflammation and arterial stiffness may contribute to the assessment of cardiovascular risk. We conducted a randomised placebo controlled trial to assess the effects of 12 weeks treatment with a PPAR alpha agonist (fenofibrate) and a PPAR gamma agonist (pioglitazone) on these parameters in obese glucose tolerant men. Arterial stiffness was measured using augmentation index and pulse wave velocity (PWV). E-selectin, VCAM-1 and ICAM-1 were used as markers of endothelial function. Insulin sensitivity improved with pioglitazone treatment (p=0.001) and, in keeping with this, adiponectin increased by 85.2% (p<0.001). Pro-inflammatory cytokine levels (TNFalpha, IL-6 and IL-1 beta) fell with both treatments (p<0.01 for TNFalpha and IL-1 beta, p<0.001 for IL-6). VCAM-1 and ICAM-1 were reduced with both treatments (p<0.001 for VCAM-1, p<0.05 for ICAM-1) and E-selectin improved with pioglitazone treatment (p=0.05). Both treatments resulted in a fall in augmentation index. PWV fell by 17.4% with fenofibrate treatment (p<0.001) and 16.3% with pioglitazone treatment (p<0.001). Pioglitazone and fenofibrate treatment of obese, glucose tolerant men reduces inflammation, improves markers of endothelial function and reduces arterial stiffness. These results suggest that treatment with PPAR agonists has potential to reduce the incidence of premature cardiovascular disease associated with obesity.
Collapse
|
7
|
Abstract
Blood levels of inflammatory markers associated with endothelial dysfunction and atherosclerosis are increased in diabetic patients; the highest levels occur in poorly controlled diabetes. We investigated the activation state of peripheral blood monocytes in diabetes with respect to scavenger receptor (CD36) expression and monocyte chemoattractant protein-1, intracellular adhesion molecule-1, vascular cell adhesion molecule-1, and peroxisome proliferator-activated receptors mRNA expression. CD14(+) monocytes were isolated from peripheral blood of type 1 and type 2 diabetic patients with good (HbA(1c) <7.0%) or poor (>9.4%) glycemic control and a group of nondiabetic subjects. Monocytes from diabetic subjects displayed increased CD36 cell surface expression (P < 0.0005) and increased uptake of oxidized LDL (P < 0.05). Monocyte chemoattractant protein-1 gene expression was increased in monocytes from both groups of diabetic subjects (P < 0.05). Both CD68 and peroxisome proliferator-activated receptor-gamma gene expression were increased in the poorly controlled diabetic group (P < 0.05 for each), whose monocytes also displayed increased attachment to endothelial monolayers (P < 0.0005 vs. nondiabetic control subjects). In poorly controlled diabetes, CD14(+) monocytes are functionally activated and show some of the differentiation markers associated with macrophages. These monocytes also demonstrate an increased ability for attachment to normal endothelial cells, one of the early stages in atherogenesis.
Collapse
Affiliation(s)
- Christine Cipolletta
- Department of Clinical Biochemistry and Metabolic Medicine, Queen's University Belfast, Institute of Clinical Science A, Grosvenor Road, Belfast BT12 6BJ, UK.
| | | | | | | |
Collapse
|
8
|
Abstract
Methods of monitoring heparin in pregnancy are problematic. The aim of this study was to assess the plasma HEPTEST as a rapid and reliable test for heparin monitoring in pregnancy. HEPTEST, activated partial thromboplastin time (APTT) and chromogenic anti-Xa assays were performed on individual heparin-spiked plasma samples from two groups: normal non-pregnant women (n = 6) and normal pregnant women during the third trimester (n = 6). Heparin activity curves were established in plasma from both groups for low (< 0.3 IU/ml), intermediate (0.3-0.7 IU/ml) and high (> 0.7 IU/ml) heparin concentrations and validated by comparison with the anti-Xa chromogenic assay. Both the APTT and HEPTEST demonstrated good correlation with anti-Xa levels across all heparin concentrations in both plasma groups (r range = 0.879-0.945). In comparison with the APTT, the HEPTEST showed better correlation with anti-Xa levels at low concentrations of heparin (r values 0.933 vs. 0.772, respectively). For both the APTT and HEPTEST there were significant differences between the clotting times in pregnant and non-pregnant plasma at a number of heparin concentrations. This data supports the plasma HEPTEST as an acceptable alternative to the chromogenic anti-Xa assay for monitoring heparin thromboprophylaxis in pregnancy.
Collapse
Affiliation(s)
- P J Campbell
- Department of Haematology, Central Middlesex Hospital, London, UK
| | | | | | | | | |
Collapse
|
9
|
Abstract
We describe five adult patients with sickle cell anaemia (SS) who developed clinical, radiological and histological evidence of splenic regrowth while receiving regular blood transfusions. Five patients, all homozygous SS, range 23-34 years, were commenced on hypertransfusion therapy. Three patients were transfused because of severe recurrent vaso-occlusive crises, one for chronic sickle lung and one in an attempt to prevent deterioration of renal function. The mean duration of hypertransfusion prior to documentation of splenic regrowth was 52 months (range 12-97 months). Two patients developed significant hypersplenism. One patient had clinically-apparent splenomegaly and four patients had splenomegaly documented on ultrasound. Splenic regrowth in hypertransfused adults with sickle cell anaemia is not infrequent and may have important clinical implications.
Collapse
Affiliation(s)
- P J Campbell
- Department of Haematology, Central Middlesex Hospital, London
| | | | | | | |
Collapse
|
10
|
Ryan KE. Mandating coverage for maternity length of stays: certain problems with the good idea. J Law Health 1995; 11:271-301. [PMID: 10176244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/23/2023]
|
11
|
Affiliation(s)
- K E Ryan
- North London Blood Transfusion Centre, Colindale, London
| | | | | | | |
Collapse
|
12
|
Ryan KE, Lane DA, Flynn A, Ireland H, Boisclair M, Shepperd J, Curtis JR. Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure. Thromb Haemost 1992; 68:563-9. [PMID: 1455403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The therapeutic potential of the glycosaminoglycan (GAG), dermatan sulphate (DS), as an antithrombotic agent in humans has yet to be established. We have performed dose ranging studies of DS to determine its effectiveness as an antithrombotic agent in patients (n = 6-8) undergoing haemodialysis for chronic renal failure. In an initial study, Study 1, i.v. bolus doses of 2-4 mg/kg and 5-6 mg/kg DS were given to patients dialysing with polyacrylonitrile hollow fibre (PAN HF) membranes. In a second crossover study, Study 2, performed using cuprophane hollow fibre (CHF) membranes, i.v. bolus doses of 3 mg/kg and 6 mg/kg DS were compared to a standard unfractionated heparin (UFH) regime that has been shown previously to inhibit fibrin formation. Further infusion studies, Study 3 and Study 4 evaluated the antithrombotic efficacy of an i.v. DS bolus of 3 mg/kg plus an i.v. infusion of DS 0.6 mg kg-1 h-1 and a DS bolus of 5 mg/kg plus an infusion of 1 mg kg-1 h-1 over 5 h, respectively. These studies were compared to standard UFH regimes in a randomised crossover design. Plasma levels of fibrinopeptide A (FPA) and thrombin-antithrombin (TAT) were used as markers of fibrin formation and thrombin generation during dialysis using both membranes. The changes in DS concentration following administration of the different doses were similar in Studies 1 and 2. However, the effectiveness of DS as an anticoagulant appeared to depend markedly on the different dialyser types used in the two studies.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- K E Ryan
- Department of Haematology, Charing Cross and Westminster Hospital, Hammersmith, London, UK
| | | | | | | | | | | | | |
Collapse
|
13
|
Ryan KE, Lane DA, Flynn A, Shepperd J, Ireland HA, Curtis JR. Dose finding study of a low molecular weight heparin, Innohep, in haemodialysis. Thromb Haemost 1991; 66:277-82. [PMID: 1745997] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
A pilot investigation was performed with Innohep, a low molecular weight (LMWH) preparation (peak maximum molecular mass 3,000-6,000), to determine possible dose regimens for patients undergoing regular maintenance haemodialysis for chronic renal failure. Results from this study suggested that suppression of macroscopic clot formation and fibrinopeptide A (FPA), a marker of fibrin formation, could be achieved following bolus injections rather than bolus injections and an infusion. On the basis of these preliminary findings, a randomised crossover study was performed in eight patients undergoing regular maintenance haemodialysis for 5-7 h to determine the effective antithrombotic dose of this LMWH. Single i.v. bolus doses of 1,250 AFXa u, 2,500 AFXa u and 5,000 AFXa u (n = 7-8) were compared to an UFH regime of 5,000 iu + 1,500 iu/h. Excessive clot formation in the dialyser bubble trap, necessitating additional UFH to enable completion of a prolonged (up to 7 h) dialysis, was observed in all patients on the 1,250 AFXa u dose (mean duration of dialysis prior to UFH, 3 h) but in a single patient only receiving the other LMWH doses. A dose-related response in the AFXa activity, measured by chromogenic substrate (CS) assay was seen in the three LMWH groups, with levels declining significantly (p less than 0.05) from 1-7 h. This contrasted with the constant levels maintained during dialysis with UFH. FPA levels were significantly elevated after 2 h following the 1,250 AFXa u bolus and after 4 h following the 2,500 AFXa u bolus. There was no significant difference in FPA levels between the 5,000 AFXa u bolus and UFH.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- K E Ryan
- Department of Haematology, Charing Cross and Westminster Medical School, London, UK
| | | | | | | | | | | |
Collapse
|
14
|
Solbach MT, Atchison TA, Ryan KE. At the core. A system measures the level of employee commitment to its core values. Health Prog 1990; 71:42-5. [PMID: 10108008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Abstract
Corporate culture has been described as the shared values that drive employee satisfaction and enhance employee commitment to the organization. Therefore system leaders must know the strength of their corporate culture. Sisters of St. Francis Health Services, Inc. (SFHS), wanted to measure whether it had a strong corporate culture based on its stated values. Executives, managers, and physicians completed surveys that assessed employee job satisfaction, commitment to the organization, and perceived strength of the system's culture. The survey achieved a 68 percent response rate. SFHS learned that it had a strong culture based on tradition and that special and unique core corporate values define "systemness" throughout its different facilities. Although each facility serves significantly different functions, leaders throughout the system make everyday decisions using the same core corporate values.
Collapse
Affiliation(s)
- M T Solbach
- Sisters of St. Francis Health Services, Mishawaka, IN
| | | | | |
Collapse
|
15
|
Hand CW, Ryan KE, Dutt SK, Moore RA, O'Connor J, Talbot D, McQuay HJ. Radioimmunoassay of buprenorphine in urine: studies in patients and in a drug clinic. J Anal Toxicol 1989; 13:100-4. [PMID: 2733386 DOI: 10.1093/jat/13.2.100] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
A radioimmunoassay kit (DPC buprenorphine double antibody) was evaluated with clinical samples and samples from a drug clinic. Urine samples were collected over a 2-day period from 5 hospital in-patients receiving sublingual buprenorphine, 400 to 2000 micrograms/day, for the relief of chronic pain. Samples were measured before and after enzymatic hydrolysis. Urine buprenorphine concentrations were measurable at all doses studied (minimum value 5.6 ng/mL) and were greater with larger doses. The increase in concentration after hydrolysis averaged 49% and was similar for all doses studied. The authors conclude that the method has extensive cross-reactivity with glucuronides of buprenorphine and its metabolites and that samples may be analyzed without prior hydrolysis. The prevalence of buprenorphine use in 97 patients attending a drug clinic was also studied. Sixty (62%) had measurable urinary buprenorphine concentrations of 1 ng/mL or more by direct assay. The buprenorphine users were significantly younger and reported significantly greater use of opiates than nonusers.
Collapse
Affiliation(s)
- C W Hand
- DPC European Research Institute, Oxfordshire, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
16
|
|